BioSpace

New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs

Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.

By BioSpace

1 min read
New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights